Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Fate Therapeutics revenue
Fate Therapeutics's revenue is $13.6 million.
What is Fate Therapeutics's revenue?
- Fate Therapeutics's revenue growth from 2012 to 2024 is 410.52%.
- Fate Therapeutics has 104 employees, and the revenue per employee ratio is $131,067.
- Fate Therapeutics's peak quarterly revenue was $59.0M in 2023(q1).
- Fate Therapeutics peak revenue was $96.3M in 2022.
- Fate Therapeutics annual revenue for 2023 was 63.5M, -34.03% growth from 2022.
- Fate Therapeutics annual revenue for 2024 was 13.6M, -78.55% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Fate Therapeutics historical revenue
Fate Therapeutics's peak revenue was $96.3M in 2022. The peak quarterly revenue was $59.0M in 2023(q1).
Fate Therapeutics's revenue increased from $2.7m in 2012 to $13.6M currently. That's a 410.52% change in annual revenue.
Fate Therapeutics annual revenue
Fate Therapeutics annual revenue over time
| Fiscal year / year | Fate Therapeutics revenue |
|---|---|
| 2012 | $2.7M |
| 2013 | $971,000 |
| 2015 | $2.4M |
| 2016 | $4.4M |
| 2017 | $4.1M |
| 2018 | $4.7M |
| 2019 | $10.7M |
| 2020 | $31.4M |
| 2021 | $55.8M |
| 2022 | $96.3M |
| 2023 | $63.5M |
| 2024 | $13.6M |
Rate Fate Therapeutics' financial transparency
Fate Therapeutics annual growth
Fate Therapeutics saw the greatest revenue growth in 2020, when revenue increased by 194.33%.
Fate Therapeutics had the lowest revenue growth in 2013, when revenue changed by -63.63%.
Fate Therapeutics annual growth rate over time
| Year | Fate Therapeutics growth |
|---|---|
| 2013 | -64%↓ |
| 2015 | 150%↑ |
| 2016 | 81%↑ |
| 2017 | -7%↓ |
| 2018 | 15%↑ |
| 2019 | 125%↑ |
| 2020 | 194%↑ |
| 2021 | 78%↑ |
| 2022 | 72%↑ |
| 2023 | -34%↓ |
| 2024 | -79%↓ |
Fate Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Fate Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | $209,000 | - |
| 2015 | - | $329,000 | $1.0M | $1.1M |
| 2016 | $1.3M | $1.0M | $1.0M | $1.0M |
| 2017 | $1.0M | $1.0M | $1.0M | $1.0M |
| 2018 | $1.0M | $1.0M | $1.0M | $1.7M |
| 2019 | $2.6M | $2.8M | $2.4M | $2.8M |
| 2020 | $2.5M | $5.5M | $7.6M | $15.9M |
| 2021 | $11.1M | $13.4M | $14.2M | $17.1M |
| 2022 | $18.4M | $18.5M | $15.0M | $44.4M |
| 2023 | $59.0M | $933,000 | $1.9M | $1.7M |
| 2024 | $1.9M | $6.8M | $3.1M | $1.9M |
Fate Therapeutics jobs nearby
Do you work at Fate Therapeutics?
Did Fate Therapeutics meet its revenue projections?
Fate Therapeutics financial information
| CEO | J. Scott Wolchko |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 104 |
| Date Founded | 2007 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $13.6M |
| Net Income | -$281,721,000 |
| PE Ratio | -5.00 |
| Market Capitalization | $930.4M |
| Total Assets | $705,561,000 |
| Ticker | FATE |
Fate Therapeutics jobs you might like
Fate Therapeutics financing
Fate Therapeutics received early financing of $12.0M on 2007-11-29.
| Series | Round size | Date |
|---|---|---|
| Series A | $12M | 11/2007 |
| Series B | $30M | 11/2009 |
| Debt Financing | $1M | 04/2011 |
| Series B | $36.0M | 05/2011 |
| Series Unknown | $9.2M | 08/2012 |
| Post Ipo Debt | $20M | 07/2014 |
| Post Ipo Equity | $8M | 05/2015 |
| Post Ipo Equity | $32M | 05/2015 |
| Post Ipo Equity | $10.3M | 08/2016 |
| Post Ipo Equity | $56.7M | 12/2016 |
| Post Ipo Equity | $42.9M | 12/2017 |
| Grant | $4M | 02/2018 |
| Post Ipo Equity | $143.8M | 09/2018 |
| Post Ipo Equity | $173M | 09/2019 |
| Post Ipo Equity | $201.3M | 06/2020 |
| Post Ipo Equity | $432M | 01/2021 |
Fate Therapeutics investors
| Investors | Security type |
|---|---|
| Polaris Partners | Series A |
| Venrock | Series A |
| ARCH Venture Partners | Series A |
| OVP Venture Partners | Series A |
| Polaris Partners | Series B |
| Astellas Venture Management LLC | Series B |
| Venrock | Series B |
| ARCH Venture Partners | Series B |
| Sanofi Ventures | Series B |
| OVP Venture Partners | Series B |
| Polaris Partners | Series B |
| Astellas Venture Management LLC | Series B |
| Venrock | Series B |
| ARCH Venture Partners | Series B |
| OVP Venture Partners | Series B |
| Silicon Valley Bank | Post Ipo Debt |
| California Institute for Regenerative Medicine | Grant |
Fate Therapeutics competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| BioTime | - | $3.4M | 101 | - |
| Genocea | - | - | 59 | - |
| TG Therapeutics | - | $329.0M | 286 | - |
| Allogene Therapeutics | - | $95,000 | 289 | - |
| Poseida Therapeutics | - | $64.7M | 200 | - |
| Minerva Biotechnologies | - | $2.4M | 24 | - |
| Neon Therapeutics | - | $1.6M | 50 | - |
| Immune Therapeutics | - | $113,500 | 2 | - |
| INmune Bio | - | $14,000 | 5 | - |
| WindMIL Therapeutics | - | $530,000 | 30 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Fate Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Fate Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Fate Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Fate Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Fate Therapeutics. The data presented on this page does not represent the view of Fate Therapeutics and its employees or that of Zippia.
Fate Therapeutics may also be known as or be related to FATE THERAPEUTICS INC, Fate Therapeutics, Fate Therapeutics Inc and Fate Therapeutics, Inc.